Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
King of Prussia, Pennsylvania--(Newsfile Corp. - November 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing therapeutic products based on its proprietary INTASYL® gene-silencing technology to eliminate cancer, today reported financial results for the quarter ended September 30, 2026, and provided a business update. "We have successfully executed on critical development objectives to advance the PH-762 program towa
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-11-05 4:05 PM EST | Phio Pharmaceuticals Corp.
iSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products
Woburn, Massachusetts--(Newsfile Corp. - November 5, 2026) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace connecting scientists who need biospecimens for medical research with a network of healthcare specimen providers, today announced that it completed, on November 2, 2026, the acquisition of two artificial intelligence products from Foldlab AI Ltd. ("Foldlab"), a British Columbia company: an AI agent that identifies disease-associated prot
2026-11-05 4:05 PM EST | iSpecimen Inc.
InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI"
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (now Mentari Therapeutics, Inc.) (the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that, subject to the satisfaction or waiver of the remaining closing conditions under the agreement and plan of merger and reorganization dated May 19, 2026 (
Biotechnologies, Pharmaceutique
2026-11-05 4:01 PM EST | InMed Pharmaceuticals
Matricelf Reports Statistically Significant Motor Function Improvement in Preclinical Efficacy Study of Chronic Spinal Cord Injury
Ness Ziona, Israel--(Newsfile Corp. - November 5, 2026) - Matricelf Ltd. (TASE: MTLF), a biotechnology company develo
2026-11-05 11:31 AM EST | Matricelf Ltd.
Solvonis Therapeutics plc Announces US Patent Office Allows Ketamine Patent Across All Behavioural Addictions
Behavioural addictions estimated to affect over 48 million Americans¹ THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOM
2026-11-05 9:21 AM EST | Solvonis Therapeutics plc
OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial
Grasonville, Maryland--(Newsfile Corp. - November 5, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has completed the requalification of drug substance used in its Phase 2b trial of OST-HER2 (Herlystic™) in the prevention of recurrence in fully resected, pulmonary metastatic osteo
2026-11-05 8:00 AM EST | OS Therapies
Zenith Epigenetics Announces Clinical Trial Collaboration and Supply Agreement with Lilly for Registration Enabling Study of ZEN-3694 and Verzenio(R) (Abemaciclib) in NUT Carcinoma
Calgary, Alberta--(Newsfile Corp. - November 5, 2026) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") today announced that the Company has executed a Clinical Trial Collaboration and Supply Agreement ("CTCSA") with Eli Lilly & Company ("Lilly") for the upcoming registration enabling study of ZEN-3694, the Company's clinical oncology candidate, and Lilly's CDK4/6 inhibitor, Verzenio (abemaciclib), for the treatment of NUT carcinoma. Under the terms of the agreement, Zenith will spons
2026-11-05 7:15 AM EST | Zenith Capital Corp.
Envoy Medical Reports Third Quarter 2026 Results and Highlights Continued Progress
White Bear Lake, Minnesota--(Newsfile Corp. - November 5, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today
Biotechnologies, Soins de santé et hôpitaux
2026-11-05 7:00 AM EST | Envoy Medical, Inc.
InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (now Mentari Therapeutics, Inc.) (the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, confirmed that, at its annual general and special meeting of shareholders held today (the "Meeting"), the matters put forward before shareholders for consideration and appr
Biotechnologies, Pharmaceutique
2026-11-04 4:51 PM EST | InMed Pharmaceuticals
Medexus Schedules Second Fiscal Quarter 2027 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - November 3, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 12, 2026, to discuss Medexus's results for its second fiscal quarter ended September 30, 2026. Medexus expects to file its financial statements and MD&A after markets close on November 11, 2026. To participate in the call, please dial the following numbers:
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-11-03 5:27 PM EST | Medexus Pharmaceuticals Inc.
InMed Reports First Quarter Fiscal 2027 Financial Results and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - November 3, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its first quarter of fiscal 2027, ended September 30, 2026, and provided a corporate update. The Company's full financial statements and related MD&A for th
Biotechnologies, Pharmaceutique
2026-11-03 7:30 AM EST | InMed Pharmaceuticals
Neural Therapeutics Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - November 2, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces a change to its Board of Directors and provides updates regarding its previously announced transaction with CWE European Holdings Inc. ("CWE"). Board of Directors The Company announces that John Durfy has resigned as Chairman and a director of the Company, effective October 26, 2026. The Company thanks Mr.
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-11-02 8:30 PM EST | Neural Therapeutics Inc.
InMed Announces Share Consolidation in Connection with Proposed Merger
Vancouver, British Columbia--(Newsfile Corp. - November 2, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that, pursuant to the previously announced agreement and plan of merger and reorganization dated May 19, 2026 (as amended, the "Merger Agreement") providing for the proposed me
Biotechnologies, Pharmaceutique
2026-11-02 4:15 PM EST | InMed Pharmaceuticals
Okogen Announces First Patient Dosed in Phase 1/2 EMERALD Trial Evaluating Treyegen for Acute Infectious Conjunctivitis
Plano, Texas--(Newsfile Corp. - November 2, 2026) - Okogen, Inc., a clinical-stage biotechnology company developing a host-directed antiviral platform, today announced that the first patient has been dosed in the EMERALD Trial, its multicenter Phase 1/2 clinical study evaluating Treyegen (OKG-0303) for acute infectious conjunctivitis. First dosing occurred at Ambade Eye Hospital in Nagpur, India. To view the full announcement, including downloadable images, bios, an
Biotechnologies, Pharmaceutique
2026-11-02 10:50 AM EST | Okogen
MustGrow Appoints Kevin Helash as Chief Executive Officer
Saskatoon, Saskatchewan--(Newsfile Corp. - November 2, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading provider of biological and regenerative agriculture solutions, today announced the appointment of Kevin Helash as Chief Executive Officer, effective November 1, 2026. Mr. Helash brings extensive international leadership experience in the agricultural industry. He previously served as CEO of Biotalys, Marrone
Agriculture, Biotechnologies, Cannabis, Sélectionneurs de cannabis
2026-11-02 7:00 AM EST | MustGrow Biologics Corp.
TempraMed Signs Exclusive UK Distribution Agreement with Poole Bay Holdings for VIVI Epi(TM), Targeting School Networks Across the UK
Highlights Definitive agreement signed October 28, 2026 appoints Poole Bay Holdings Ltd. as exclusive UK distributor of VIVI Epi™ for an initial 24-month term, subject to UK regulatory requirements. Contractual minimum purchase to maintain exclusivity. The initial two-year minimum volumes represent approximately US$198,000 in potential purchases. Poole Bay Holdings reports 20 specialist e-commerce sites an
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-11-02 7:00 AM EST | TempraMed Technologies Ltd.
iSpecimen Offers Next-Day Healthy Donor Blood and Launches Development of AI Agent
Woburn, Massachusetts--(Newsfile Corp. - October 29, 2026) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), a provider of human biospecimens, today announced expanded access to fully consented, prospectively collected healthy donor whole blood through an existing collection partner. The expanded capability gives researchers a streamlined option for sourcing whole blood collected specifically for research. Specimens are generally shipped directly from the collection site o
2026-10-29 4:10 PM EDT | iSpecimen Inc.
PharmaTher Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157
Toronto, Ontario--(Newsfile Corp. - October 29, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical and technology company advancing pharmaceutical 3D printing for personalized medicine, today announced that it is building a portfolio of personalized peptide products for niche indications on its M3DICINES™ 3D-printed medicines platform, for near-term commercialization through the new U.S. peptide pathway. The first prod
Biotechnologies, Pharmaceutique
2026-10-29 10:01 AM EDT | PharmaTher Holdings Ltd.
BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026
British Columbia and Rehovot, Israel--(Newsfile Corp. - October 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will report its third quarter 2026 financial results before the market opening on Thursday, November 12, 2026. The Company will host a conference call and webcast at 8:00 AM Eastern Time to
Biotechnologies, Pharmaceutique, Santé
2026-10-29 8:00 AM EDT | BioHarvest Sciences Inc.
Enodia Therapeutics Appoints Henrik Torp Nielsen as Chief Financial Officer to Support Corporate Growth and Strategic Development
Paris, France--(Newsfile Corp. - October 29, 2026) - Enodia Therapeutics, a biotechnology company developing small-molecule therapies targeting a unique form of protein degradation at the point of synthesis, appointed Henrik Torp Nielsen as Chief Financial Officer. With nearly two decades of experience in biopharma finance and operations, Mr. Nielsen will lead Enodia's financial strategy and operations as the company advances its proprietary Sec61 platform. Enodia's approa
2026-10-29 7:20 AM EDT | Enodia Therapeutics